Adherence to Guidelines for Glucose Assessment in Starting Second-Generation Antipsychotics

    Basic Details
    Date
    Monday, October 6, 2014
    Type
    Publication
    Medical Product
    aripiprazole
    olanzapine
    quetiapine
    risperidone
    second generation antipsychotic (SGA)
    Health Outcome(s)
    baseline glucose assessment
    Description

    This article describes the findings of a study conducted to evaluate baseline glucose assessment among youth ages 2 through 18 starting a second-generation antipsychotic in the United States.

    Information
    Time Period
    2006 - 2011
    Population / Cohort
    All children 2 through 18 years of age
    Data Source(s)
    Mini-Sentinel Distributed Database (MSDD)
    Author(s)

    Marsha Raebel PharmD; Robert Penfold PhD; Ann McMahon MD, MSc; Marsha Reichman PhD; Susan Shetterly MS; Glenn Goodrich MS; Susan Andrade ScD; Christoph Correll MD; Tobias Gerhard PhD

    Corresponding Author

    Marsha Raebel, Institute for Health Research, Kaiser Permanente Colorado, PO Box 378066, Denver, CO 80237, USA. Email: Marsha.A.Raebel@kp.org